Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Establishment Labs Holdings Inc. (NASDAQ: ESTA) provides access to the company’s U.S. regulatory disclosures as a global medical device issuer focused on breast aesthetics and reconstruction. Through these documents, investors can review how Establishment Labs reports its financial condition, operating results, and key corporate agreements.
Core filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company details revenue from its portfolio of breast health, breast aesthetics, and breast reconstruction products, as well as expenses, liquidity, and risk factors. These reports also describe its manufacturing operations in Costa Rica, quality system compliance under ISO 13485:2016 and FDA 21 CFR 820, and its intellectual property position, including patent applications and clinical evidence supporting its devices.
Current reports on Form 8-K are particularly relevant for tracking material events at Establishment Labs. Recent 8-K filings have covered earnings announcements for specific quarters and an amendment to the company’s credit agreement with Oaktree Fund Administration, LLC, including the availability of additional term loan tranches and related liquidity requirements. Such filings help clarify changes in capital structure, borrowing capacity, and other significant developments.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the content of complex filings. Users can quickly understand the implications of new 10-K and 10-Q reports, 8-K current events, and other submissions without reading every page. The platform also surfaces insider transaction disclosures on Form 4, allowing users to monitor equity transactions by Establishment Labs’ directors and officers as reported to the SEC.
Establishment Labs Holdings insider Filippo Caldini, who serves as both Chief Executive Officer and a director, reported purchases of 2,850 common shares of the company on 08/11/2025. The Form 4 shows a weighted average purchase price of $35.2 and reports total direct beneficial ownership after the transaction of 35,245 shares. The filing states the trades were executed in multiple transactions at prices ranging from $34.00 to $35.00 and that the reporting person will provide a full breakdown of shares purchased at each price upon request. No derivative securities were reported.
The Form 4 filing reports a routine equity compensation transaction for Establishment Labs Holdings Inc. (ESTA) director Nicholas Sheridan Lewin. On 30 June 2025, Lewin elected to receive 585 common shares in lieu of his quarterly cash retainer, valued at $42.71 per share under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan. Following the grant, Lewin’s direct ownership increased to 1,075,923 shares, while he also indirectly owns 14,190 shares held by his spouse. No derivative securities were involved, and there were no dispositions. The filing indicates continued board-level alignment with shareholders but does not represent a material change in Lewin’s overall stake or the company’s share structure.